Abstracts tagged "SLE"

Abstract Number: 1817 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach
Wei Fu¹ and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease with extreme variability of its activity over time. We have described three main patterns: long…
Abstract Number: 2811 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Ioanna Giannakou¹, Katerina Chatzidionysiou², Noémi Györi³, Laurence S Magder⁴, Ronald F. van Vollenhoven^5,6 and Michelle Petri⁷, ¹Department of Medicine, Karolinska Institute, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Unit, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a variability of disease expression, both between individuals and within individuals, over time. The aim of this…
Abstract Number: 2937 • 2016 ACR/ARHP Annual Meeting
Regulation of Follicular Helper T (TFH) Cells By ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Woelsung Yi¹, Sanjay Gupta², Chien-Huan Weng³, Yurii Chinenov⁴, James K. Liao⁵ and Alessandra B. Pernis⁶, ¹Hospital for Special Surgery, New York, NY, ²Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁵Cardiology Section, University of Chicago Medical Center, Chicago, IL, ⁶David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Follicular helper T (TFH) cells promote humoral responses and serve as a limiting factor for the selection of high affinity germinal center B cells.…
Abstract Number: 122 • 2016 ACR/ARHP Annual Meeting
A Small Number of Patients with SLE Account for Most of the Direct and Indirect Hospitalization Costs
Allen P. Anandarajah¹, Bethany A. Marston², Debbie Campbell³ and Christopher T. Ritchlin⁴, ¹Dept of Rheumatology, Univ of Rochester Med Ctr, Rochester, NY, ²Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems and is associated with high morbidity. Studies have shown…
Abstract Number: 966 • 2016 ACR/ARHP Annual Meeting
Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Gaurav Gulati¹, Michael Bennett², Khalid Abulaban^3,4, Qing Ma⁵, Marisa S. Klein-Gitelman⁶, Kelly A. Rouster-Stevens⁷, Christopher Haffner⁵, Kasha Wiley⁸, Stacy P. Ardoin⁹, Jun Ying¹⁰, Prasad Devarajan¹¹ and Hermine I. Brunner⁸, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Helen DeVos Children's Hospital, Grand Rapids, MI, ⁵Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ¹⁰Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Dept of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Renal Activity In Lupus (RAIL) Urinary Biomarkers Predict Treatment Response Background/Purpose: We have previously demonstrated the strong predictive value of the Renal Activity In Lupus…
Abstract Number: 1387 • 2016 ACR/ARHP Annual Meeting
Evaluation of Mild to Moderate SLE Flare in Patients with Childhood-Onset Disease
Malki Peskin¹, Dawn Wahezi^2,3, Chaim Putterman⁴, Tamar Rubinstein^5,6 and Nicole Jordan^4,7, ¹Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ³Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁶Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁷Montefiore Medical Center, New York, NY
Background/Purpose: One aspect of childhood SLE lacking understanding is the prediction of disease flares. The objective of this study is to identify predictors of mild…
Abstract Number: 1828 • 2016 ACR/ARHP Annual Meeting
Metabolic Reprogramming in CD4+CD28-CXCR3intt-bethi cells and Its Relevance to Pathogenesis in Patients with SLE
Shigeru Iwata¹, Yuka Kanno², Kei Sakata^3,4, Maiko Hajime¹, Masataka Torigoe^1,5, Naoaki Ohkubo¹, Shingo Nakayamada⁶, John J O'Shea⁷ and Yoshiya Tanaka⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyshu, Japan, ⁵Department of Endocrinology, Metabolism, Rheumatology and Nephrology,, Faculty of Medicine, Oita University, Yufu, Oita, Japan, Yufu, Japan, ⁶First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: CD4+ T cells play a crucial role in pathological process of Systemic Lupus Erythematosus (SLE). Recently, importance of metabolic reprograming in immunocompetent cells was…
Abstract Number: 2815 • 2016 ACR/ARHP Annual Meeting
Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
Juliana Valim¹, Verônica Lima², Fernanda Guimarães³, Fernanda Chaer⁴ and Branca Souza⁵, ¹Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ²Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
Background/Purpose: To Compare the induction therapy of lupus nephritis with cyclophosphamide (CYC) high dose or low dose and identify possible predictors of disease remission. Methods:…
Abstract Number: 2984 • 2016 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse
Jie An¹, Joshua Woodward², Mark Minie³, Xizhang Sun⁴, Lena Tanaka¹, Yufeng Peng¹, Jessica Snyder⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Type I interferon, (IFN-I) is strongly implicated in the pathogenesis of SLE as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres Syndrome (AGS) caused…
Abstract Number: 124 • 2016 ACR/ARHP Annual Meeting
Socioeconomic-Demographic, Disease Activity, Treatment and Immunologic Variables Affect B Cell Subtypes in Systemic Lupus Erythematosus
Arlene Bravo¹, Michelle T. Ngo², Michael De Vera³, Karina Marianne D. Torralba^2,4 and Abigail Benitez^2,4, ¹Internal Medicine, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Transplantation Institute, Loma Linda University, Loma Linda, CA
Background/Purpose: B cell subset proportions within the B cell pool, also known as B cell signatures (BCS), reflect not only systemic lupus erythematosus (SLE) disease…
Abstract Number: 968 • 2016 ACR/ARHP Annual Meeting
Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
Ranjan Gupta¹, Akhilesh Yadav² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Alternatively activated (M2) macrophages are the major macrophage subtype infiltrating the glomeruli in lupus nephritis (LN). CD163 is a marker of M2 macrophages. In…
Abstract Number: 1388 • 2016 ACR/ARHP Annual Meeting
Distinct Clinical Correlates of Immune Thrombocytopenic Purpura at Diagnosis of Childhood-Onset and Adult SLE
Gladys Esteves¹, Natali W. Gormezano², Oriany Pereira¹, David Kern¹, Katia T. Kozu², Rosa M R Pereira³, Clovis A Silva⁴, Eloisa Bonfa⁵ and Nadia E Aikawa⁶, ¹University of São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Rheumatology, University of São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁶Rheumatology Division, University of São Paulo, São Paulo, Brazil
Background/Purpose: Hematologic abnormalities are common manifestations in systemic lupus erythematosus (SLE) patients. Several studies have demonstrated a higher frequency of immune thrombocytopenic purpura (ITP) in…
Abstract Number: 1829 • 2016 ACR/ARHP Annual Meeting
Hyper-Responsiveness to TLR-4 Stimulation in SLE: Association with High Levels of Serum IFN-Alpha and a Distinct Inflammatory Cytokine Profile
Uma Thanarajasingam¹, Mark A. Jensen², Jessica M. Dorschner³, Danielle Vsetecka³, Shreyasee Amin⁴, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁴, Vaidehi Chowdhary⁴ and Timothy B. Niewold⁶, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: IFN-alpha is a pathogenic factor in SLE. High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with double-stranded DNA (dsDNA) antibodies.…
Abstract Number: 2830 • 2016 ACR/ARHP Annual Meeting
Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus
Laura Durcan¹, Armin Zadeh², Margery Connelly³, James Otvos³, Laurence S Magder⁴ and Michelle Petri⁵, ¹University of Washington, Seattle, WA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³LabCorp, Raleigh, NC, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) associates with atherosclerotic cardiovascular (CV) disease and related mortality. This is contributed to, but cannot be fully explained, by traditional…
Abstract Number: 2989 • 2016 ACR/ARHP Annual Meeting
Risk of Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort
Medha Barbhaiya¹, Candace H. Feldman¹, Sarah K. Chen², Hongshu Guan³, Tzu-Chieh Lin¹, Michael A. Fischer⁴, Daniel H. Solomon⁵, Brendan M. Everett⁶ and Karen H. Costenbader¹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in SLE patients compared to non-SLE patients. However, how CVD rates differ in SLE patients compared with other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].